Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreatic Cancer
Clinical trial register · United States · industry-sponsored

Pancreatic Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 26 Florida 24 Texas 17 New York 15 Arizona 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Revolution Medicines, Inc.5 Varian, a Siemens Healthineers Company2 A2 Biotherapeutics Inc.2 Astellas Pharma Global Development, Inc.2 ViroMissile, Inc.1
State
California26 Florida24 Texas17 New York15 Arizona12
All 38 states
Target enrolment
to

Pancreatic Cancer trials in the USA

43 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
NCT07828236Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
Loki Therapeutics, Inc.
Phase 1
18
New York
2026-10-15
Not yet open
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07325214Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Not applicable
360
Massachusetts, Texas, Virginia
2026-09
Recruiting
Revolution Medicines, Inc.
Phase 3
400
Florida
2026-08-28
Recruiting
Anova Innovation Limited
Phase 1/2
84
California
2026-08
Recruiting
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
NCT07824583Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
Varian, a Siemens Healthineers Company
Not applicable
20
Missouri, Ohio
2026-07-31
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Recruiting
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
NCT07542041Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Lesions Located at the Body or the Tail
ARTIDIS AG
Not applicable
200
Florida
2026-04-17
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsODM-212·Gemcitabine and nab-paclitaxel·Ipilimumab and nivolumab·Sotorasib
Orion Corporation, Orion Pharma
Phase 1/2
229
Texas, Virginia
2026-03-27
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
SONIRE Therapeutics Inc.
Early Phase 1
10
California
2026-01-05
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
DrugIDOV-Immune
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Lantheus Medical Imaging
Phase 1/2
26
California, Michigan, Ohio
2025-08
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Alpha Tau Medical LTD.
Not applicable
50
Arizona, California, Florida, Georgia, New York, Texas
2025-06-17
Recruiting
EXoPERT EMERALD Clinical Study
NCT07186296Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
EXoPERT
Observational
1,400
California, Hawaii, Kentucky, Maryland, New York
2025-05-09
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Active, closed
Prestige Biopharma Limited
Phase 1/2
80
New York
2023-06-05
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
134
Alabama, California, Missouri, Ohio
2023-05-14
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
160
Arizona, California, Florida, Minnesota, Missouri, New York, Texas
2023-04-28
Active, closed
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Active, closed
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
A2 Biotherapeutics Inc.
Observational
500
Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio
2021-10-29
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
CARsgen Therapeutics Co., Ltd.
Phase 1/2
110
California, Florida, Kansas, Michigan, Minnesota, New York, Ohio, Texas
2020-10-23
Recruiting
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
DrugsFolfox·Oxaliplatin
Bold Therapeutics, Inc.
Phase 1/2
220
California, Florida
2020-08-28
Recruiting
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT04157127Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Diakonos Oncology Corporation
Phase 1
18
Texas
2020-08-03
Active, closed
ImmunityBio, Inc.
Phase 2
328
California, New Jersey, South Dakota
2020-07-21
Active, closed
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
DrugsTST001·MFOLFOX6·Albumin-Bound Paclitaxel·Opdivo
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
150
Arizona, Connecticut, Florida, Georgia, Kansas, Missouri, New York, North Carolina
2020-05-28
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Missouri
2019-03-15
Active, closed
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
DrugsCCNU·Lomustine·Abraxane·Adriamycin
Actuate Therapeutics Inc.
Phase 2
350
Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa, Kansas
2019-01-04
Active, closed
Viewray Inc.
Not applicable
133
California, Florida, Massachusetts, Michigan, Missouri, New Hampshire, New York, Oregon
2019-01-01
Recruiting
CivaTech Oncology
Phase 1/2
80
Florida, Illinois, Louisiana, Pennsylvania, Virginia
2017-05-31
Active, closed
Incyte Corporation
Phase 2
10
California, Kentucky, New York, Tennessee, Texas
2016-11-30
Recruiting
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Lumicell, Inc.
Phase 1/2
66
Massachusetts
2016-08-04
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/pancreatic-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies listing the condition Pancreatic Cancer.

How many Pancreatic Cancer trials are recruiting in the US?

25 of the 43 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Cancer), 43 studies
PhaseStudiesRecruitingShare
Phase 1/213630.2%
Phase 110623.3%
Phase 37616.3%
Not applicable6414%
Phase 2409.3%
Observational224.7%
Early Phase 1112.3%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Cancer)
Lead sponsorStudiesRecruiting
Revolution Medicines, Inc.54
A2 Biotherapeutics Inc.21
Astellas Pharma Global Development, Inc.21
Varian, a Siemens Healthineers Company22
Actuate Therapeutics Inc.10
Alpha Tau Medical LTD.11
Anova Innovation Limited11
ArriVent BioPharma, Inc.11
ARTIDIS AG11
AstraZeneca10

Top states

Top states (Pancreatic Cancer), by number of studies with a site there
StateStudies
California26
Florida24
Texas17
New York15
Arizona12
Massachusetts10
Missouri9
Michigan8
Virginia8
Georgia7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.